奈达铂联合紫杉醇治疗晚期宫颈癌的临床观察

发布时间：2018-04-20 12:16

本文选题：晚期宫颈癌 + 奈达铂　；参考：《中国药房》2017年15期

【摘要】：目的:观察奈达铂联合紫杉醇治疗晚期宫颈癌的疗效和安全性。方法:100例晚期宫颈癌患者随机分为对照组(50例)和观察组(50例)。两组患者均采用6MV直线加速器外放射联合腔内后装照射。在此基础上,对照组患者静脉滴注顺铂注射液20mg/m~2,d_1+紫杉醇注射液35 mg/m~2,d_1,3 h内滴完;观察组患者静脉滴注注射用奈达铂20 mg/m~2,d_1+紫杉醇注射液(用法用量同对照组)。两组均以1周为1个周期,共治疗6个周期。观察两组患者的近期疗效,治疗前后血管内皮生长因子A(VEGF-A)、VEGF-C、VEGF-D水平和微淋巴管密度(LVD)、微血管密度(MVD)及毒副反应发生情况。结果:观察组患者总有效率(52.00%)、疾病控制率(86.00%)均显著高于对照组(分别为32.00%、66.00%),差异均有统计学意义(P0.05)。治疗后,两组患者VEGF-A、VEGF-C、VEGF-D水平和LVD、MVD均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05)。观察组患者血小板减少发生率显著高于对照组,恶心呕吐发生率显著低于对照组,差异均有统计学意义(P0.05)。结论:奈达铂联合紫杉醇可提高晚期宫颈癌患者的近期疗效,降低VEGF水平及抑制肿瘤血管生成,减少胃肠道反应,但应注意血小板毒性反应。
[Abstract]:Objective: to observe the efficacy and safety of neidplatin combined with paclitaxel in the treatment of advanced cervical cancer. Methods 100 patients with advanced cervical cancer were randomly divided into control group (n = 50) and observation group (n = 50). The patients in both groups were treated with 6MV linear accelerator combined with intracavitary irradiation. On this basis, 20 mg / m-1 paclitaxel injection 35 mg / m-1 paclitaxel injection was injected intravenously in the control group within 3 hours, and 20 mg / mm-1 paclitaxel injection was injected intravenously in the observation group in the same dosage as the control group. The two groups were treated for 6 cycles in 1 week. To observe the short-term curative effect of the two groups, the level of vascular endothelial growth factor (VEGF) VEGF-D, the density of microlymphatic vessel (LVDN) and microvessel density (MVDD) and the occurrence of side effects before and after treatment. Results: the total effective rate (52.00) and the disease control rate (86.00) in the observation group were significantly higher than those in the control group (32.00 and 66.00, respectively), and the difference was statistically significant (P 0.05). After treatment, the levels of VEGF-C VEGF-D and LVD- MVD in the two groups were significantly lower than those in the control group, and the difference between the two groups was statistically significant (P 0.05). The incidence of thrombocytopenia in observation group was significantly higher than that in control group, and the incidence of nausea and vomiting was significantly lower than that in control group (P 0.05). Conclusion: neidaplatin combined with paclitaxel can improve the short-term efficacy of advanced cervical cancer, reduce the level of VEGF, inhibit tumor angiogenesis, and reduce gastrointestinal reaction, but we should pay attention to platelet toxicity.
【作者单位】：河南大学淮河医院妇产科;
【分类号】：R737.33

【相似文献】